# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $8 price target.
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4...
Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $6 to $7.
HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $8 price target.
Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focused on discovering, d...
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.21) by 4.7...
Capital One analyst Naureen Quibria initiates coverage on Erasca (NASDAQ:ERAS) with a Overweight rating and announces Price ...
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initia...